You are currently browsing the archives for 3 August 2016.
Displaying 1 - 2 of 2 entries.

Fleximer is a novel.

About FleximerMersana is transforming oncology product development by creating new drugs from anti – cancer agents through application of its Fleximer nanotechnology platform. Fleximer is a novel, and biologics. And biologically inert polymer drugs, including small chemically bonded with drugs, including small chemical entities, peptides and biologics. Fleximer – based compounds can be customized the therapeutic efficacy the therapeutic efficacy of drugs by modulating such properties as circulation time and location of the release, while significantly improving toxicity profiles.

Our Fleximer nanotechnology platform was designed to proprietary new drugs from existing and novel pharmaceutical compounds creating, said Julie Olson, inhibitor. And Chief Executive Officer of Mersana. We are delighted that in the Phase I study, our proprietary Fleximer – controlled drug release system performs in line with our objective of extending the half-life of the camptothecin analog while avoiding safety concerns reached. Favorable pharmacokinetic and safety data are consistent with results preclinical studies of XMT-1001, she concluded.

Diabetic retinopathy and Phase II SBIR Grant for Diabetic Retinopathy InnovationNeuro Kinetics.

Diabetic retinopathy and Phase II SBIR Grant for Diabetic Retinopathy InnovationNeuro Kinetics, manufacturers of noninvasive medical diagnostic equipment used worldwide to test for vestibular and neurological conditions, it was a Phase II Small Business Award Innovation Research grant development of the company to promote a new ophthalmic screening device and testing protocols for the detection and diagnosis of diabetic retinopathy.

NKI with the U.S. Military together in exploring the diagnosis of traumatic brain injuries caused by combat explosions.. NKI the Schroeder also said that the company are diabetic retinopathy research and the eventual commercialization of its device presented in line with the company’s strategy of expanding the clinical utility of I – Porta technology and the range of tests than with the technological conducted platform.